A61K 31/424
Condensed with heterocyclic ring systems
Official title: condensed with heterocyclic ring systems, e.g. clavulanic acid
A61K31/424 (Condensed with heterocyclic ring systems) appears on 210 US grants and 359 published applications in this corpus.
Search patents in A61K- Granted patents
- 210
- Published applications
- 359
- Assignees
- 202
- Inventors
- 975
- Latest grant
- 18 Aug 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1996 | 1 | 0 |
| 1997 | 2 | 0 |
| 1998 | 1 | 0 |
| 1999 | 2 | 0 |
| 2000 | 8 | 0 |
| 2001 | 1 | 3 |
| 2002 | 5 | 7 |
| 2003 | 4 | 11 |
| 2004 | 4 | 12 |
| 2005 | 5 | 12 |
| 2006 | 6 | 14 |
| 2007 | 9 | 11 |
| 2008 | 1 | 13 |
| 2009 | 4 | 8 |
| 2010 | 6 | 13 |
| 2011 | 2 | 12 |
| 2012 | 7 | 13 |
| 2013 | 7 | 15 |
| 2014 | 7 | 17 |
| 2015 | 13 | 19 |
| 2016 | 15 | 17 |
| 2017 | 17 | 19 |
| 2018 | 12 | 16 |
| 2019 | 8 | 19 |
| 2020 | 13 | 25 |
| 2021 | 10 | 14 |
| 2022 | 9 | 11 |
| 2023 | 8 | 11 |
| 2024 | 11 | 19 |
| 2025 | 7 | 15 |
| 2026 | 5 | 13 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- RXFP1 agonists18 Aug 2026US 12,709,594 B2Bristol-Myers Squibb Company
- Macrocyclic compounds, compositions, and methods of using thereof9 Jun 2026US 12,649,750 B2Genzyme Corporation
- Macrocyclic compounds, compositions, and methods of using thereof12 May 2026US 12,624,051 B2Genzyme Corporation
- Spiromacrocyclic orexin 2 receptor agonists31 Mar 2026US 12,590,106 B2H. Lundbeck A.S.
- Cyclodextrin complexes of specialized proresolving mediators3 Mar 2026US 12,564,644 B2Thetis Pharmaceuticals LLC
- Lysine acetyltransferase 6a (kat6a) inhibitor, combinations and uses thereof1 Oct 2026US 2026/0294884 A1Insilico Medicine IP Limited
- Tetraline, phenylcyclobutane and phenylcyclopentane analogs as rxfp1 agonists10 Sep 2026US 2026/0265208 A1Bristol-Myers Squibb Company
- Benzothiophene derivatives as rxfp1 agonists10 Sep 2026US 2026/0265233 A1Bristol-Myers Squibb Company
- Chromane amidine monobactam compounds for the treatment of bacterial infections3 Sep 2026US 2026/0258029 A1Merck Sharp & Dohme Corp.
- Pharmaceutical combination for the treatment of multiple myeloma, monoclonal gammopathy of undetermined significance, and smoldering multiple myeloma9 Jul 2026US 2026/0191834 A1
Most cited
By later US patents
- Methods of diagnosing and treating small intestinal bacterial overgrowth (SIBO) and SIBO-related conditions198US 7,048,906 B2Cedars-Sinai Medical Center · 2006
- Methods for manipulating upper gastrointestinal transit, blood flow, and satiety, and for treating visceral hyperalgesia84US 7,081,239 B2Cedars-Sinai Medical Center Burns and Allen Research Center · 2006
- Methods of diagnosing small intestinal bacterial overgrowth (SIBO) and SIBO-related conditions78US 7,736,622 B2Cedars-Sinai Medical Center · 2010
- Methods for manipulating satiety77US 7,608,245 B2Cedars-Sinai Medical Center · 2009
- Methods for manipulating upper gastrointestinal transit, blood flow, and satiety, and for treating visceral hyperalgesia75US 7,244,412 B2Cedars-Sinai Medical Center · 2007